Impax Laboratories Completes Combination With Amneal Pharmaceuticals

May 4, 2018

S&C represents Impax Laboratories, Inc., a leading specialty pharmaceutical company, consummated its business combination with Amneal Pharmaceuticals LLC, one of the largest generic brands pharmaceutical companies in the United States, in an all-stock transaction.

The S&C team advising Impax was led by Frank Aquila and Matthew Hurd, along with Julia Kim, Amanda Gill, Natalie Lum-Tai, Yilong Luo and Lisa Morales. Nader Mousavi, along with Mark Schenkel, Justin Orr, Nicole Sharer. Matthew Rosenberg advised on intellectual property matters; Heather Coleman, along with Joshua Green advised on executive compensation and benefits matters. Ari Blaut, along with Brian Farber and Emily Hantverk advised on financing matters; Catherine Clarkin, along with Brian Farber and Jennifer Lee advised on securities law matters; Ronald Creamer, along with Dana Brodsky advised on tax matters; Matthew Brennan advised on environmental matters; and Joseph Neuhaus and Laura Oswell advised on litigation matters. Annie Zhou and Steven Mermelstein provided valuable assistance on multiple aspects of the transaction.